Asset Details
Do you wish to reserve the book?
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
Do you wish to request the book?
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
2002
Overview
This randomized trial involved 160 patients with the acquired immunodeficiency syndrome (AIDS) and newly diagnosed cytomegalovirus retinitis. After four weeks, the response to induction therapy was satisfactory in 72 percent of patients who received oral valganciclovir, as compared with 77 percent of those who received intravenous ganciclovir. The median time to progression of retinitis was 160 days for the valganciclovir group and 125 days for the ganciclovir group.
Cytomegalovirus retinitis remains the leading cause of visual loss in patients with the acquired immunodeficiency syndrome (AIDS).
1
–
3
Induction therapy with intravenous ganciclovir,
4
,
5
foscarnet,
5
,
6
or cidofovir,
7
,
8
followed by maintenance therapy, can effectively make cytomegalovirus retinitis inactive. If recovery of immune function is not possible, indefinite treatment is needed, and an indwelling catheter and daily intravenous medication may be required. The cost, the risk of sepsis, and the adverse effect on the quality of life associated with an indwelling catheter spurred the development of an oral formulation of ganciclovir.
9
When administered orally, ganciclovir requires three doses (up to . . .
Publisher
Massachusetts Medical Society
Subject
Acquired Immunodeficiency Syndrome - complications
/ Adult
/ AIDS-Related Opportunistic Infections - drug therapy
/ AIDS-Related Opportunistic Infections - pathology
/ Antiviral Agents - pharmacokinetics
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Cytomegalovirus - isolation & purification
/ Cytomegalovirus Retinitis - drug therapy
/ Cytomegalovirus Retinitis - pathology
/ Eye
/ Female
/ Ganciclovir - analogs & derivatives
/ Ganciclovir - pharmacokinetics
/ Ganciclovir - therapeutic use
/ HIV
/ HIV - isolation & purification
/ Human immunodeficiency virus
/ Humans
/ Male
